Medical News Today
Allergan, Inc. (NYSE:AGN) announced that the U.S. Food and Drug Administration has approved COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. COMBIGAN™ is the newest addition to Allergan's comprehensive glaucoma portfolio, which also includes LUMIGAN® (bimatoprost ophthalmic solution) 0.03% and ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%.